Early Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 75 years old.
- You have been diagnosed with acute myeloid leukemia (AML) based on 2016 WHO standards, and either cannot receive standard treatments, or your AML has come back or stopped responding after at least 2 previous rounds of treatment.
- Your leukemia has either returned in your blood or bone marrow after a period of remission, or it did not respond well to standard chemotherapy treatments (confirm with trial site for your specific situation).
- You are generally well enough to carry out basic daily activities, rated 0–2 on a standard medical fitness scale (meaning you may have some symptoms but are not completely unable to care for yourself).
- Your doctor expects you to live for at least 12 weeks.
- Your major organs (such as your liver and kidneys) are working at a normal or near-normal level.
Who may not be able to join:
- You have a specific type of leukemia called acute promyelocytic leukemia (APL).
- You have a serious bleeding problem or your blood does not clot properly, or you are currently taking clot-dissolving medication.
- You have active tuberculosis (TB), are currently being treated for TB, or were treated for TB within the past year.
- You are living with HIV, or you have an active syphilis infection.
- You have taken certain medications that suppress the immune system within 1 week before starting the trial (some exceptions apply — confirm with trial site).
- You have received a live vaccine (such as certain flu, MMR, or yellow fever vaccines) within 2 weeks before starting the trial, or plan to receive one during the study.
- You have taken part in another clinical trial and received an experimental treatment within the past 4 weeks.
- You have taken certain immune-boosting medications (such as interferons or thymosin) within 2 weeks before starting the trial (some exceptions apply — confirm with trial site).
- You have active hepatitis B (with a certain level of virus detected in your blood) or hepatitis C infection.
- Your doctor has any other concern that makes them feel this trial would not be safe or appropriate for you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: zhiguo Long, Shanghai Pudong Hospital
Phone: 13817651474
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-Limiting Toxicity; Complete Response Rate (CRR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.